ClinicalTrials.gg
CompletedNCT01026389DALIAUpdated Dec 11, 2012Results posted

Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease

A Phase 4 interventional study of Dotarem and Gadovist in Peripheral Arterial Disease, sponsored by Guerbet. Completed at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-12-11.

Sponsored by Guerbet · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
189
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 74 studies in Peripheral Arterial Disease with a site in Austria — 7 open to participants now, 16 under way, 2 of them phase 3. Peripheral Arterial Disease · Austria.

Enrollment
29th of 58
189 · median 170
Started
2009
the only one that year
Phase 4
4 of 74
none open now
Registered
8th of 74
by date

Among the 74 studies in Peripheral Arterial Disease with a site in Austria, this one is the 29th largest by enrollment of the 58 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 4, and was the 8th registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 74 studies in Peripheral Arterial Disease with a site in Austria are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Peripheral Arterial Disease with a site in Austria, or all of them as a file.
02

Study summary

This study is an efficacy evaluation of Dotarem®-enhanced magnetic resonance angiography (MRA) compared to Gadovist®-enhanced MRA in the diagnosis of clinically significant abdominal or lower limb arterial diseases.

03

Conditions studied

  • Peripheral Arterial Disease

Keywords

  • MRA-Contrast agent comparison in peripheral disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged ≥ 18 years.
  • Patient with infrarenal aorta or chronic lower limb ischemia with various clinical signs of gravity (stages II-IV according to the classification of Leriche and Fontaine) or/and Doppler ultrasonography indicating abdominal or lower limb arteriopathy.
  • Patient scheduled for a conventional X-Ray angiography (intra-arterial Digital Substraction Angiography = DSA) within 30 days of MRA with a minimum time interval of at least 24 hours between the 2 examinations.

Exclusion criteria

Exclusion Criteria:

  • Patient planned to undergo therapeutic intervention in abdominal or lower limb vessels between the time of MRA and X-ray Angiography will be performed.
  • Patient who had a major cardiovascular event within 30 days prior to the inclusion.
  • Patient treated with unilateral hip replacement, abdominal aortic or iliac graft or stent.
05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
189 participants (actual)

Study arms

  • Active comparator
    Gadovist

    Patient received contrast-enhanced MRA with Gadovist

    Drug: Gadovist

  • Experimental
    Dotarem, interventional

    Patients received contrast-enhanced MRA with Dotarem

    Drug: Dotarem

Interventions

  • DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus

    Also known as: gadoterate, Gd-Dota

  • Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus

    Also known as: gadobutrol

06

What researchers measure

Primary outcomes

  1. Intra-patient Accuracy (Percent Agreement), On-site Data

    intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography.

    Time frame: up to one month

Secondary outcomes

  1. Intra-patient Accuracy, in Off-site Readings

    • Intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography, in off-site readings, using the same methodology as that used for the primary criterion

    Time frame: up to one month

  2. Specificity

    Specificity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site readings; no stenosis and non significant stenosis were grouped as one class (non significant stenosis = negative segment).

    Time frame: up to one month

  3. Sensitivity

    sensitivity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site; moderate, severe stenosis and occlusion were grouped as one class (significant stenosis = positive segment).

    Time frame: up to one month

07

Results

Posted Dec 11, 2012

Participant flow

Recruitment period between october 2009 and January 2011. Patients were recruited in hospitals.

Participant flow — Overall Study
MilestoneGadovistDotarem
Started9393
Completed8888
Not completed55
Withdrew: Withdrawal by subject13
Withdrew: Change of treatment, patient moved42

Outcome measures

PrimaryIntra-patient Accuracy (Percent Agreement), On-site Data

intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography.

Time frame:
up to one month
Reported as:
Mean · percentage of agreement
Intra-patient Accuracy (Percent Agreement), On-site Data
percentage of agreementGadovistDotarem, Interventional
Intra-patient Accuracy (Percent Agreement), On-site Data77.1 ± 19.680.6 ± 16.1
SecondaryIntra-patient Accuracy, in Off-site Readings

• Intra-patient accuracy (percent agreement) of each type of MRA examination (Dotarem® or Gadovist®-enhanced MRA) in assessing the lesions of the concerned territory as compared with the gold standard, X-ray angiography, in off-site readings, using the same methodology as that used for the primary criterion

Time frame:
up to one month
Reported as:
Mean · percentage of agreement
Intra-patient Accuracy, in Off-site Readings
percentage of agreementGadovistDotarem, Interventional
Intra-patient Accuracy, in Off-site Readings75.1 ± 15.373.9 ± 16.7
SecondarySpecificity

Specificity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site readings; no stenosis and non significant stenosis were grouped as one class (non significant stenosis = negative segment).

Time frame:
up to one month
Reported as:
Number · negative segments in MRA
Specificity
negative segments in MRAGadovistDotarem, Interventional
Specificity756763
SecondarySensitivity

sensitivity of Dotarem® and Gadovist®-enhanced MRA examinations at the segment and the patient levels (gold standard = x-ray angiography) in on-site; moderate, severe stenosis and occlusion were grouped as one class (significant stenosis = positive segment).

Time frame:
up to one month
Reported as:
Number · positive segment with MRA
Sensitivity
positive segment with MRAGadovistDotarem, Interventional
Sensitivity168191

Adverse events

Collected over 15 months in total For each patient, adverse events were collected from signature of inform consent form to the end of the DSA. Non-serious events are listed at a 0.01% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gadovist—0/93 (0%)2/92 (2.2%)
Dotarem, Interventional—1/93 (1.1%)2/92 (2.2%)
Most frequent serious events
Most frequent serious events
EventGadovistDotarem, Interventional
Acute coronary syndromeCardiac disorders0/931/93
carotid stenosisNervous system disorders0/931/93
Most frequent other events
Most frequent other events
EventGadovistDotarem, Interventional
FolliculisInfections and infestations0/921/92
contrast extravasationGeneral disorders1/920/92
burningNervous system disorders0/921/92
heat sensation in the faceVascular disorders1/920/92

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)GadovistDotarem, InterventionalTotal
<=18 years000
Between 18 and 65 years484896
>=65 years454590
Age Continuous
Age Continuous(years)GadovistDotarem, InterventionalTotal
Mean66.5 ± 10.266.8 ± 10.666.7 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)GadovistDotarem, InterventionalTotal
Female211839
Male7275147
Region of Enrollment
Region of Enrollment(participants)GadovistDotarem, InterventionalTotal
Austria191837
France162036
Germany7714
Italy161632
Spain353267
08

Study locations

1 site
  • AKH hospital
    Wien, Austria
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jun 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2009
First posted
Dec 4, 2009
Start
Oct 2009
Primary completionActual
Jun 2011
CompletionActual
Jan 2012
Results first posted
Dec 11, 2012
Last update
Dec 11, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01026389
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Oct 2009
Primary completion
Jun 2011
Completion
Jan 2012
Results posted
Dec 11, 2012
Last update
Dec 11, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoterate meglumine

Start the discussion